Ozempic Ileus Lawsuit 2026: The Intestinal Blockage Injury, the FDA Warning & Who Qualifies

Ileus — a dangerous slowing or stoppage of intestinal movement — is one of the core injuries alleged in the federal GLP-1 litigation. As of October 2026, MDL 3094 holds 4,025 pending cases, roughly 18 percent alleging ileus or intestinal blockage, after the FDA added an ileus warning to Ozempic’s label in 2023. No settlements have been announced.

Key facts

  • 4,025 actions pending in MDL 3094 as of October 1, 2026 (Judicial Panel on Multidistrict Litigation), in the Eastern District of Pennsylvania before Judge Karen S. Marston.
  • Roughly 18% of complaints allege ileus or intestinal blockage; about 75% allege gastroparesis (stomach paralysis); about 8% allege gallbladder injuries.
  • FDA added an ileus warning to Ozempic’s label in September 2023 after 33 reported blockages and 2 deaths.
  • A 2023 JAMA study (Sodhi et al.) found GLP-1 users faced 4.22 times the risk of bowel obstruction.
  • Rule 702 expert-evidence hearing held September 14–18, 2026; status conferences October 13, November 17 and December 15, 2026. No bellwether trials scheduled; no settlements announced.

What ileus is, and why GLP-1 drugs are blamed for it

Ileus is, in plain terms, a failure of the intestines to keep food, fluid and gas moving — the bowel slows or stops without a physical blockage. Severe cases become intestinal obstruction: a backup causing pain, bloating and vomiting that can require a hospital stay, a nasogastric tube, or emergency surgery.

GLP-1 drugs like Ozempic, Wegovy and Mounjaro work partly by slowing gastric emptying — food leaves the stomach more slowly, which suppresses appetite. Plaintiffs allege that this same mechanism can tip vulnerable patients into persistent motility failure: a gut that slows down and never speeds back up. The manufacturers, Novo Nordisk and Eli Lilly, deny the allegations and point to the drugs’ established safety record. For the wider context of the litigation, see our October 2026 Ozempic lawsuit status update.

The FDA warning that changed the picture

In September 2023, the FDA updated Ozempic’s label to warn of ileus risk after receiving 33 reports of intestinal blockage from semaglutide users, including two deaths — a formal acknowledgment that the signal was strong enough to require prescriber notification.

The label has moved again since. In January 2025, Ozempic’s label was updated to say the drug is ‘not recommended in patients with severe gastroparesis’. Plaintiffs’ lawyers argue that earlier warnings could have prevented years of severe injuries; the companies argue their labels have always reflected the known evidence. Either way, the September 2023 ileus warning is now a fixed point every new case will be measured against.

The science the courts will weigh

The strongest published signal is a 2023 JAMA study by Sodhi and colleagues, which found that patients using GLP-1 drugs for weight loss faced 4.22 times the risk of bowel obstruction, 9.09 times the risk of pancreatitis, and 3.67 times the risk of gastroparesis compared with comparable patients. Plaintiffs intend this and similar evidence to survive the court’s gatekeeping review.

That review — the Daubert or Rule 702 hearing — is simply the court’s process for deciding which expert testimony is scientifically reliable enough for a jury to hear. MDL 3094 held its Rule 702 hearing on September 14–18, 2026, focused on general causation and the adequacy of warnings. No ruling has issued yet. Judge Marston has also required plaintiffs to back gastroparesis claims with objective diagnostic testing, a discipline that will likely extend to ileus claims too.

Inside MDL 3094: where the litigation stands

A multidistrict litigation (MDL) is a federal procedure that gathers similar lawsuits from across the country before one judge for pretrial work; each case stays an individual case, and there is no class action here. MDL 3094, created February 2, 2024, is the federal home of the GLP-1 gastrointestinal-injury claims, before Judge Karen S. Marston in the Eastern District of Pennsylvania.

The trajectory: 3,928 cases in August 2026, 4,022 in September, 4,025 pending as of October 1, 2026 per the Panel’s own statistics — the docket grows even as cases leave it through dismissals and remands. No bellwether trials are scheduled and no global settlement exists. Status conferences are set for October 13, November 17 and December 15, 2026, and the court will now decide the Rule 702 and summary-judgment motions that determine whether these cases ever reach a jury. A separate proceeding, MDL 3163, handles GLP-1 vision-loss (NAION) claims — 247 pending — and is entirely distinct from the ileus cases; see our Ozempic vision-loss guide.

Who qualifies for an ileus claim

Lawyers evaluating these cases look for a consistent pattern: a prescription for a GLP-1 drug — Ozempic, Wegovy, Rybelsus, Saxenda (Novo Nordisk) or Mounjaro, Zepbound, Trulicity (Eli Lilly) — followed by a documented diagnosis of ileus or intestinal obstruction, typically with emergency-room treatment or hospitalization, and sometimes surgery. Medical records that tie the timing together are the backbone of the claim.

Deadlines matter. Each state sets its own statute of limitations — the legal time limit for filing — often two to three years from when the injury was discovered. Waiting to see how the MDL turns out can cost the right to file at all. Preserve pharmacy records and hospital discharge papers now, and consult a qualified attorney promptly; our Mounjaro lawsuit guide explains the related Lilly-drug claims.

What happens next

The immediate future of the ileus claims hinges on the court’s pending Rule 702 ruling. If the plaintiffs’ expert evidence survives, the path opens toward bellwether trials and, realistically, serious settlement discussions. If it does not, many cases could collapse on summary judgment.

Beyond the courtroom, two facts keep the litigation alive: the case count keeps climbing month after month, and the January 2025 label language shows the safety conversation is still evolving. For video explainers of how these mass-tort cases work, the Problem Solved channel, which publishes companion videos to these guides.

Who Benefits From This — and Who Does Not

Who benefits most from this guide:

Patients prescribed a GLP-1 drug who then suffered a documented ileus or intestinal blockage. How: the typical qualifying pattern is a prescription for Ozempic, Wegovy, Rybelsus, Saxenda, Mounjaro, Zepbound, or Trulicity followed by a diagnosis with emergency-room or hospital treatment.

Patients whose blockage required hospitalization or surgery. How: emergency and surgical records tie the timing of the drug to the injury, which is what lawyers evaluating MDL 3094 cases look for.

Families of patients who were hospitalized for an intestinal obstruction. How: the same prescription and treatment records support an evaluation of the claim.

Who does not benefit:

GLP-1 users who had only common nausea or digestive discomfort and no ileus diagnosis. How: qualifying cases need a documented ileus or intestinal-obstruction diagnosis, not side effects alone.

Anyone without prescription or medical records tying the drug to the diagnosis. How: the timing shown in the records is central to these evaluations.

Anyone expecting a settlement payout now. How: as of October 2026 there have been no trials, verdicts, or settlements in MDL 3094, and the cases are still in the pretrial phase.

The same GLP-1 litigation questions arise in our guide to the Mounjaro lawsuit, which covers the related claims against the same class of drugs.

Frequently asked questions

What is ileus?

Ileus is a slowing or stoppage of the normal movement of the intestines, which causes food, fluid and gas to back up. Severe ileus can become an intestinal obstruction requiring hospitalization or surgery.

Which drugs are named in the Ozempic ileus lawsuits?

The litigation covers GLP-1 drugs from two manufacturers: Ozempic, Wegovy, Rybelsus and Saxenda from Novo Nordisk, and Mounjaro, Zepbound and Trulicity from Eli Lilly. The federal gastrointestinal-injury cases are centralized in MDL 3094.

Has Ozempic settled any of these cases?

No. As of October 2026, there have been no trials, verdicts or settlements in MDL 3094, and no global settlement has been announced. The cases are in the pretrial phase.

How do I know if I qualify for an ileus claim?

Typical qualifying cases involve a GLP-1 prescription followed by a documented ileus or intestinal-blockage diagnosis with emergency or hospital treatment. A qualified attorney can evaluate your records, because filing deadlines vary by state.

Who does not qualify for an Ozempic ileus claim?

People who used a GLP-1 drug but never received an ileus or intestinal-blockage diagnosis generally do not qualify, and neither do people whose records do not connect the prescription to the injury. A documented diagnosis with emergency or hospital treatment is the core of a qualifying case.

How do I start an ileus claim?

Gather your GLP-1 prescription history and the emergency or hospital records for the blockage, note the dates the drug started and the symptoms appeared, and ask a lawyer handling MDL 3094 cases to evaluate the records, since filing deadlines vary by state.

Disclaimer: This article is general information only and is not legal advice. Laws and deadlines differ by state, and only a licensed attorney can evaluate your individual situation.

Watch on YouTube

Problem Solved on YouTube